Black Rock Inc. Pharma Cyte Biotech, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 13,346 shares of PMCB stock, worth $13,479. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,346
Previous 21,104
36.76%
Holding current value
$13,479
Previous $50,000
48.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding PMCB
# of Institutions
29Shares Held
674KCall Options Held
13.7KPut Options Held
2.1K-
Vanguard Group Inc Valley Forge, PA195KShares$196,4630.0% of portfolio
-
Geode Capital Management, LLC Boston, MA139KShares$140,3240.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$93,0077.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$83,5540.08% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny49.5KShares$49,9950.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $21M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...